Primary diagnoses and primary cytotoxic therapies in 306 patients who developed therapy-related myeloid leukemia: the University of Chicago series.4
| Primary diagnosis . | No. of patients . | Chemotherapy only (%) . | Radiotherapy only (%) . | Combined modality therapy (%) . |
|---|---|---|---|---|
| * Numbers in parentheses are percentages for each row of data according to primary therapy. | ||||
| † In 3 patients, the primary therapy was incompletely known. | ||||
| No Prior Malignancy | 18 | 12 (67)* | 2 (11) | 4 (22) |
| Hematologic Malignancy | 171 | 69 (40) | 5 (3) | 97 (57) |
| Hodgkin lymphoma | 77 | 18 (23) | 4 (5) | 55 (71) |
| Non-Hodgkin lymphoma | 70 | 33 (47) | 1 (1) | 36 (51) |
| Myeloma | 23 | 17 (74) | 0 | 6 (26) |
| Other | 1 | 1 (100) | 0 | 0 |
| Solid Tumors | 117 | 40 (35) | 36 (32) | 38 (33) |
| Breast | 32 | 11 (35) | 5 (16) | 15 (48) |
| Ovary | 15 | 12 (80) | 1 (7) | 2 (13) |
| Prostate | 13 | 0 | 11 (100) | 0 |
| Lung | 9 | 5 (56) | 2 (22) | 2 (22) |
| Cervix | 7 | 0 | 4 (57) | 3 (43) |
| Other | 41 | 12 (30) | 13 (32) | 16 (39) |
| Total | 306† | 121 (40) | 43 (14) | 139 (46) |
| Primary diagnosis . | No. of patients . | Chemotherapy only (%) . | Radiotherapy only (%) . | Combined modality therapy (%) . |
|---|---|---|---|---|
| * Numbers in parentheses are percentages for each row of data according to primary therapy. | ||||
| † In 3 patients, the primary therapy was incompletely known. | ||||
| No Prior Malignancy | 18 | 12 (67)* | 2 (11) | 4 (22) |
| Hematologic Malignancy | 171 | 69 (40) | 5 (3) | 97 (57) |
| Hodgkin lymphoma | 77 | 18 (23) | 4 (5) | 55 (71) |
| Non-Hodgkin lymphoma | 70 | 33 (47) | 1 (1) | 36 (51) |
| Myeloma | 23 | 17 (74) | 0 | 6 (26) |
| Other | 1 | 1 (100) | 0 | 0 |
| Solid Tumors | 117 | 40 (35) | 36 (32) | 38 (33) |
| Breast | 32 | 11 (35) | 5 (16) | 15 (48) |
| Ovary | 15 | 12 (80) | 1 (7) | 2 (13) |
| Prostate | 13 | 0 | 11 (100) | 0 |
| Lung | 9 | 5 (56) | 2 (22) | 2 (22) |
| Cervix | 7 | 0 | 4 (57) | 3 (43) |
| Other | 41 | 12 (30) | 13 (32) | 16 (39) |
| Total | 306† | 121 (40) | 43 (14) | 139 (46) |